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Abstract 
Background: Delayed cerebral ischemia (DCI) is a major cause of morbidity 
and mortality in aneurysmal subarachnoid hemorrhage. Endovascular 
management of this condition offers a new hope in preventing adverse 
outcome, however a uniform standard of practice is lacking owing to a paucity 
of clinical trials. We conducted an international survey on the use of 
investigative and endovascular techniques in the treatment of DCI in order to 
assess the variability of current practice.  Methods:  Neurovascular 
neurosurgeons and neuroradiologists were contacted via professional 
societies from America, United Kingdom, Europe and Australasia. Members 
were invited to complete a 13-item questionnaire regarding screening 
techniques, first- and second-line therapies in endovascular intervention, and 
the role of angioplasty. Answers were compared using chi-square testing for 
nonparametric data. Results: Data from 344 respondents from 32 countries 
were analyzed: 167 non-US and 177 US respondents. More than half of all 
clinicians had more than 10 years of experience in units with a mixture of 
higher and lower case volumes. Daily transcranial Doppler ultrasonography 
was the most commonly used screening technique by both US (70%) and 
non-US (53%) practitioners. Verapamil was the most common first-line 
therapy in the United States, whereas nimodipine was most popular in non-
US countries. Angioplasty was performed by 83% of non-US and 91% of US 
clinicians in the treatment of vasospasm; however, more US clinicians 
reported using angioplasty for distal vasospasm. Conclusions: Treatment 
practices for DCI vary considerably, with the greatest variability in the choice 
of agent for intra-arterial therapy.  Our data demonstrate the wide variation of 
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approaches in use today; however, without further clinical trials and 
development of a uniform standard of best practice, variability in treatment 
and outcome for DCI is likely to continue.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Results of an International Survey on the Investigation and Endovascular 
Management of Cerebral Vasospasm and Delayed Cerebral Ischemia 
 
Milo Hollingworth MBBS1,2, Peng Roc Chen MD3, Antony JP Goddard FRCR4, 
Alan Coulthard FRCR5, Michael Söderman MD6, Ketan R. Bulsara MD1 
  
1Yale Department of Neurosurgery, USA 
2 University College London, United Kingdom 
3
 University of Texas Medical School at Houston, USA 
4Leeds General Infirmary, United Kingdom 
5 University of Queensland, Australia 
6.Karolinska Hospital and Institute, Sweden 
Corresponding Author: Dr Milo Hollingworth MBBS 
    333 Cedar Street, TMP 4 
    New Haven, CT 06524 
    Phone:  203-737-2096 
    Fax:  203-785-2044 
    E-mail: milohollingworth@gmail.com 
 
Cover Title:  Cerebral Vasospasm Management: An International Survey 
Keywords:  cerebral vasospasm;subarachnoid hemorrhage, delayed cerebral 
ischemial; intra-arterial treatment, transcranial Doppler, angioplasty, survey  
Word count: 3175 (+ 4 figures, 1 table and 1 supplemental material) 
 
Abstract 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Background: Delayed cerebral ischemia (DCI) is a major cause of morbidity 
and mortality in aneurysmal subarachnoid hemorrhage. Endovascular 
management of this condition offers a new hope in preventing adverse 
outcome, however a uniform standard of practice is lacking owing to a paucity 
of clinical trials. We conducted an international survey on the use of 
investigative and endovascular techniques in the treatment of DCI in order to 
assess the variability of current practice.  Methods:  Neurovascular 
neurosurgeons and neuroradiologists were contacted via professional 
societies from America, United Kingdom, Europe and Australasia. Members 
were invited to complete a 13-item questionnaire regarding screening 
techniques, first- and second-line therapies in endovascular intervention, and 
the role of angioplasty. Answers were compared using chi-square testing for 
nonparametric data. Results: Data from 344 respondents from 32 countries 
were analyzed: 167 non-US and 177 US respondents. More than half of all 
clinicians had more than 10 years of experience in units with a mixture of 
higher and lower case volumes. Daily transcranial Doppler ultrasonography 
was the most commonly used screening technique by both US (70%) and 
non-US (53%) practitioners. Verapamil was the most common first-line 
therapy in the United States, whereas nimodipine was most popular in non-
US countries. Angioplasty was performed by 83% of non-US and 91% of US 
clinicians in the treatment of vasospasm; however, more US clinicians 
reported using angioplasty for distal vasospasm. Conclusions: Treatment 
practices for DCI vary considerably, with the greatest variability in the choice 
of agent for intra-arterial therapy.  Our data demonstrate the wide variation of 
approaches in use today; however, without further clinical trials and 
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development of a uniform standard of best practice, variability in treatment 
and outcome for DCI is likely to continue.  
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Introduction  
Subarachnoid haemorrhage (SAH) accounts for only 5% of stroke, however it 
carries considerable mortality of up to 40% (1). This is in part related to 
phenomena of delayed cerebral ischemia (DCI), which has been reported to 
occur in 29% of SAH (2). DCI, typically occurring occurring 3-14 days after 
aneurismal rupture (2), refers to a temporary or permanent focal or global 
neurological deficit that can result in cerebral infarction and death (3). The 
pathogenesis of DCI is complex involving cellular, humoral and genetic 
factors; however, central to its development is cerebral vasospasm (4). 50% 
of patients with angiographic vasospasm develop delayed ischemic 
neurological deficits with resultant stroke or death (5-7). So intimately linked 
are DCI and cerebral vasospasm, that the terms are often used 
interchangeably (3). Importantly, however, DCI and cerebral vasospasm may 
occur independently of one another with DCI occurring in the absence of 
cerebral vasospasm and visa versa (8). Problems with nomenclature have 
lead to inconsistencies between studies and so, in keeping with contemporary 
concensus (3), vasospasm will solely be used to describe the angiographic 
phenomena of cerebrovascular constriction herein. Nevertheless, the 
outcome for patients suffering DCI is significant. Attempts have been made to 
improve outcome with various systemic therapies (4), however advances 
have been made regarding endovascular techniques providing mechanical (9-
11) and pharmaceutical splinting of cerebral vasculature (12,13). However, 
there is a paucity of clinical trials regarding which endovascular therapies 
deliver superior outcomes, with the neurocritical care community concluding 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
that too many small, uncontrolled, often retrospective studies provide little 
definitive guidance on the subject (14). This lack of clarity has given rise to 
significant variability in practice amongst US endovascular interventionalists 
(15). We aimed to investigate variability in international practice and compare 
management strategies between US and non-US clinicians. By analysing data 
from members of American Association of Neurological Surgeons/Congress 
of Neurological Surgeons (AANS/CNS) Cerebrovascular Section, the British 
Society of Neuroradiologists (BSNR), the European Society of 
Neuroradiologists (ESNR), and the interventional section of the Australian and 
New Zealand Society of Neuroradiology (ANZINC), we compare international 
perspectives from America, United Kingdom, Europe and Australiasia on the 
management of DCI. By gaining insight into current practice around the world, 
we aim to explore differences in management strategies and suggest possible 
hypotheses for future study, which could one day lead to a uniform standard 
of best practice regarding investigation and endovascular therapy for DCI and 
cerebral vasospasm. 
 
Methods 
 A survey was designed and distributed to practitioners worldwide via 
the AANS/CNS, BSNR, ESNR and ANZINC. Surveys were distributed via e-
mail to every active member (Supplementary material 1).  The survey 
consisted of 13 questions on screening techniques, choice of first- and 
second-line therapies in endovascular intervention, and the role of 
angioplasty. The responses were collected anonymously. Data collection was 
conducted among AANS/CNS members in June 2012 (15) and was extended 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
to the ESNR, BSNR, and ANZINC members in November 2013. Data 
collection was conducted over a 3-month period and reminder e-mails were 
sent to all members before the survey deadline. Statistical analysis was 
undertaken with SPSS Version 21 (IBM Corp, Armonk, NY) for chi-square 
testing for nonparametric data.  
Results 
A total of 344 responses were collected from the AANS/CNS, ESNR, 
BSNR and ANZINC members, from whom we received 177, 102, 32, and 23 
responses respectively. The response rates were reported between 16-40%.  
Responses were subdivided into 177 US and 167 non-US responses. The 
latter included practitioners from 32 different countries (Table 1).  
The proportion of respondents with more than 10 years of experience 
in practice was not significantly different between the US and non-US 
respondents (p-value > 0.05). 57% percent of non-US respondents (96/167) 
and 60% of US respondents (106/177) had more than 10 years of experience, 
and only 16% (27/167) and 21% (37/177) of non-US and US respondents, 
respectively, had less than 5 years of experience (Figure 1A).  Both groups 
had high case loads of aneurysmal SAH, although the case load was higher 
among non-US respondents, with 44% (75/167) reporting more than 100 
cases of aneurysmal SAH per year compared with 25% of US respondents 
(44/177). Only 5% (9/167) and 11% (19/177) of non-US and US respondents, 
respectively, managed fewer than 25 cases per year (Figure 1B).  
Reported screening methods for DCI demonstrated significant 
variability both between US and non-US countries and within the US itself 
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(Figure 1C). Daily transcranial Doppler (TCD) ultrasonography was the most 
commonly used technique overall; 58% of respondents (208/344) reporting 
using daily TCDs.  53% of non-US respondents (90/167) and 70% of US 
respondents (123/177) reported using daily TCDs. Computed tomography 
angiography (CTA) conducted between days 5 and 10 was the next most 
commonly used screening tool, reported by 15% of respondents (54/344). 
Routine angiogram at 5 to 10 days was reported by 13% (45/344) of 
respondents overall. Both routine CTA and angiography were more commonly 
reported by US than by non-US respondents at 23% (40/177) versus 9% 
(15/167) and 24% (41/177) versus 5% (8/167), respectively. Other methods of 
DCI screening included computer tomography perfusion (CTP), magnetic 
resonance spectroscopy (MRS), magnetic resonance angiography (MRA), 
digital subtraction angiography (DSA), and electroencephalography (EEG). 
CTP was used by more than one respondent, which was reported by 5 US 
and 6 non-US respondents. The differences in use of screening methods 
between US and non-US respondents were statistically significant in all cases 
(p-value < 0.05). 
In 60% of cases (209/344), practitioners began DCI treatment only if 
clinical symptoms were present. However, US respondents were more likely 
to initiate treatment on the basis of radiographic evidence of cerebral 
vasospasm, with 54% of US respondents (95/177) saying they would do so 
compared with only 26% of non-US respondents (44/167; Figure 2A; p-value 
< 0.05). To begin treatment for DCI, 91% of the total respondents (313/344) 
would maximize critical care management; however, a minority of both US 
and non-US respondents would proceed straight to endovascular treatment 
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(Figure 2B).  However, 93% of non-US respondents (156/167) and 95% of US 
respondents (168/177) would use endovascular intervention in the 
management of DCI (Figure 2C).  
Respondents were invited to select their first-line and second-line 
endovascular therapies from papaverine, milrinone, verapamil, or nimodipine 
or to enter their own preference. Data were grouped by the respective 
pharmaceutical agents, including other endovascular therapies commonly 
volunteered by respondents, which included angioplasty and nimodipine. 
Other options that were less commonly volunteered such as glyceryl trinitrate 
and fasudil hydrochloride were grouped under Other. Responses to questions 
that specified endovascular therapy that did not include endovascular 
therapies were excluded. There was significant variation both within and 
between groups regarding first-line endovascular therapy (Figure 3A). Among 
US practitioners, verapamil was used by 56% of respondents (93/168), while 
nicardipine, papaverine, milrinone, and nimodipine were used by 25% 
(42/168), 7% (12/168), 3% (5/168), and 3% (5/168), respectively. Other first-
line therapies chosen by US respondents included fasudil hydrochloride, 
angioplasty, and angioplasty in combination with pharmaceutical agents. 
Among non-US respondents, verapamil was not the most commonly used 
first-line agent; verapamil was used by only 6% of non-US respondents 
(9/156). The most common first-line agent chosen by the non-US respondents 
was nimodipine, which was used by 74% (116/156). Other therapies used by 
non-US clinicians were nicardipine, milrinone, papaverine, and angioplasty by 
3% (5/156), 2% (3/156), 6% (9/156), and 6% (9/156), respectively.  
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A total of 80% of respondents (277/344) reported using a second-line 
endovascular therapy, which also varied between countries. For second-line 
therapies, larger proportions of respondents opted for angioplasty (Figure 3B): 
26% (37/143) and 11% (15/134) of respondents in non-US countries and the 
US, respectively. However, the majority of respondents opted for 
pharmacological agents. As a second-line therapy, 27% (36/134), 26% 
(34/134), and 19% (25/134) of US respondents chose verapamil, nicardipine, 
and papaverine, respectively. Interestingly, 3% of US respondents (4/134) 
opted to use glyceryl trinitrate; however, only 1 US respondent opted to use 
nimodipine. Second-line therapies used by non-US respondents included 
nimodipine, verapamil, papaverine, milrinone, and nicardipine, which were 
selected by 34% (48/143), 9% (14/143), 19% (27/143), 7% (10/143), and 4% 
(6/143), respectively (Figure 3B).  
Respondents were also asked to describe the association between 
their first-line endovascular therapy and immediate angiographic effect as 
“always,” >80%, >50%, <50%, or 10-30%. This was associated with marked 
variability. However, the reported data suggested that nimodipine was more 
commonly associated with an immediate angiographic response than was 
verapamil. 52% (62/117) of responders using nimodipine as a first-line 
therapy reported an immediate angiographic response always or at least 80% 
of the time.  Only 42% (50/117) of verapamil users, however, reported an 
immediate response always or at least 80% of the time (Figure 3C). 
Angioplasty was used by the majority of US and non-US groups, which was 
reported by 91% (162/177) and 83% (139/167), respectively (Figure 4A). 
However, 23% of US practitioners (39/168) used angioplasty for distal 
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vasospasm compared with 6% (8/139) of non-US respondents (Figure 4B), 
which was a statistically significant difference (p-value < 0.05). In response to 
the question, “What is the best endovascular therapy for DCI?” the most 
popular opinion was angioplasty (161/344 of respondents; Figure 4C). 51% 
(90/167) and 61% (107/177) of non-US and US respondents agreed that 
treatments involving angioplasty offer superior outcomes, which suggests a 
prevailing view worldwide that angioplasty is the best treatment for DCI 
Discussion 
We present the results of an international survey of the management of 
DCI by both US and non-US practitioners. The majority of responders were 
experienced clinicians with high numbers of SAH cases per year. We found 
significant variability between the US and the rest of the world in current 
practice regarding both screening methods and treatment options. We also 
found significant variability among US respondents in the first- and second-
line therapies chosen. 
Our results suggest that screening is more commonly used by US 
clinicians; however, the use is far from ubiquitous, with only 70%, 23%, and 
24% of the total sample using daily TCDs, routine CTA, and routine 
angiography, respectively.  Furthermore, some centers inside and outside the 
US use different techniques such as CTP, the efficacy of which offers an 
interesting hypothesis for further study.  
The explanation of the disparity between use of screening methods 
between US and non-US respondents is unclear. Whether it pertains to 
resource availability or different perspectives on best practice remains to be 
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seen. Nevertheless the effect of screening methods on the outcome of DCI 
needs to be further elucidated to ensure a cost-efficient strategy with optimal 
clinical outcome.  
Most US and non-US clinicians agreed that maximal critical care 
management should be attempted as a first-line therapy. However, again 
major differences in practice were apparent regarding the use of angioplasty 
and different intra-arterial pharmaceutical agents. Verapamil was commonly 
reported as a first-line therapy by US respondents, whereas nimodipine was 
seldom used. By contrast, most non-US clinicians used nimodipine and 
verapamil less so.  Data regarding the choice and dose of intra-arterial 
therapy are limited (14). Indeed, according to self-reported data regarding 
immediate angiographic changes following endovascular intervention, more 
clinicians saw an immediate angiographic response following nimodipine 
administration versus verapamil. However, the extent to which this would 
correlate with clinical outcome is unclear, considering that 82% to 100% of 
patients have angiographic improvement but 23% to 69% still go on to suffer 
cerebral ischemia (9-11). Nevertheless, the use of nimodipine versus 
verapamil presents an interesting and worthwhile hypothesis for study with 
worldwide implications.  
This survey of current practitioners was dependent on self-report. The 
survey does not represent the practice of all practitioners worldwide and it 
offers a limited view of current practices. It is difficult to estimate the number 
of clinics or proportion of clinicians our data represent owing to our method of 
online survey distribution. Response rate was estimated by AANS/CNS, 
BSNR, ESNR and ANZINC between 16-40%, however the institutions cited 
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limitations in calculating response rates owing to many members who are not 
actively involved in the management of DCI and some respondents answering 
on behalf of their hospital comprising a number of clinicians. Indeed, this 
survey also did not account for the different backgrounds of respondents. 
Endovascular therapies can be utilized by both neurosurgeons and 
neuroradiologists depending on local policy. It is unclear whether this would 
affect practice and may offer an interesting avenue of study. Nevertheless, 
with 344 respondents in 32 different countries, this study offers the most 
comprehensive insight into contemporary international DCI management 
practices currently available. 
 Although we cannot infer efficacy of treatments or suggest protocols 
for screening methods, this survey suggests several interesting hypotheses 
for further investigation. This includes how outcome could be affected by 
using daily TCD and routine vascular imaging techniques, the choice of 
pharmaceutical agents, and the use of angioplasty. Moving forward, it will be 
critical to define appropriate and accurate outcome parameters, for registries 
or prospective trials, to reliably identify which agents or strategies may be 
superior in the management of DCI.   
To this end, we have initiated the Intra-arterial Vasospasm Trial (IVT; 
NCT01996436 on clinicaltrial.gov). The IVT is an ongoing multicenter 
randomized trial across America recruiting over 200 patients with DCI 
refractory to standard hospital care. By random assignment of intra-arterial 
agents (nicardipine, milrinone, verapamil or a combination of nicardipine, 
verapamil and nitroglycerin) via endovascular catheter, these patients will 
form the basis of a randomized trial designed to identify the most efficacious 
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intra-arterial agents. Primary outcome parameters include changes in post-
infusion vessel caliber 10 minutes after agent infusion, while secondary 
outcome parameters will measure morbidity and mortality using the Modified 
Rankin score 6 weeks post-hospital discharge.  It is a hope that this will mark 
the beginning of an evidenced based approach to achieve a uniform standard 
of best practice for the endovascular management of DCI and cerebral 
vasospasm 
Conclusion 
344 respondents from 32 different countries offered their expertise regarding 
the management of DCI providing a comprehensive insight into available 
practices worldwide.  This survey demonstrates important differences in 
practice both within the United States and compared to the rest of the world. 
Such variations in screening methods and endovascular therapy should 
prompt further clinical trials, including the extension of the IVT outside the US, 
in order to achieve a universally recognized standard of best practice for this 
challenging therapeutic dilemma.  
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 Figure legends 
Figure 1. A) US (n=177) and non-US (n=167) clinicians reported years 
experience managing subarachnoid haemorrhage: Less than 5 years (US 
21%; non-US 16%), 5-10 years (US 18%; non-US 24%) and over 10 years 
(US 57%; non-US 60%); B) US (n=177) and non-US (n=167) clinicians 
reported annual case loads of subarachnoid haemorrhage: less than 25 (US 
11%; non-US 5%), 25-50 (US 26%; non-US 20%), 50-100 (US 34%; non US 
34%)  and over 100 (US 25%; non-US 44%)  cases per year; C) US (n=177) 
and non-US (n=167) clinicians reported use of delayed cerebral ischemia 
screening technique: the most common method was daily transcranial 
Dopplers (US 70%; non-US 53%) other common options included routine 
computer tomography angiography (between days 5-10) (US 23%; non-US 
9%) and routine angiogram (between days 5-10) (US 24%; non-US 5%). 
Differences between US and non-US countries in use of screening methods 
met statistical significance in all cases (p-value< 0.05). 
Figure 2. A) The difference between US (n=177) and non-US (n=167) 
responders treating delayed cerebral ischemia on the basis of radiological 
cerebral vasospasm alone differed with statistical significance (US 54%; Non-
US 26%; p-value<0.05); B) Initial therapy reported by US (n=177) and non-US 
(n=167) responders most commonly included intensive care treatment (US 
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91%; Non-US 91%) compared to endovascular therapy (US 9%; Non-US 9%); 
C) The majority of both US (n=177) and non-US (n=167) respondents used 
endovascular therapy in the treatment of delayed cerebral ischemia (US 93%; 
Non-US 95%) 
Figure 3. A) US (n=168) and non-US (n=156) practitioners reported first-line 
endovascular therapy: angioplasty (US 3%; non-US 6%), milrinone (US 3%; 
non-US 2%), nicardipine (US 25%; non-US 3%), nimodipine (US 3%; non-US 
74%), papaverine (US 7%; non-US 6%), verapamil (US 56%; non-US 6%) 
and other agents (US 2%; non-US 0%) including fasudil hydrochloride. B) US 
(n=134) and non-US (n=142) practitioners reported second-line endovascular 
therapy: angioplasty (US 11%; non-US 26%), milrinone (US 4%; non-US 7%), 
nicardipine (US 26%; non-US 4%), nimodipine (US 1%; non-US 34%), 
papaverine (US 19%; non-US 19%), verapamil (US 27%; non-US 9%) and 
other agents (US 3%; non-US 0%) including glyceryl trinitrate ; C) US and 
non-US practitioners (n=324) reported immediate angiographic responses 
following first-line endovascular therapy as Always, more than 80%, more 
than 50%, 10-30% or Never. Each endovascular therapy was associated with 
varying degrees of reported immediate angiographic response.  
Figure 4. A) 95% of US (n=177) and 83% of non-US (n=167) responders 
reported using angioplasty in the management of delayed cerebral ischemia; 
B) Use of angioplasty for distal cerebral vasospasm was highest amongst US 
(n=168) respondents at 23% versus 6% for non-US (n=139) respondents; this 
reached statistical significance (p-value<0.05); C)US (n=177) and non-US 
(n=167) practitioners answered the question “What is the best endovascular 
therapy for delayed cerebral ischemia?”  the most common response was 
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angioplasty (US 61%; Non US 51%), other choices included milrinone (US 
1%; non-US 2%), nicardipine (US 3%; non-US 0%), nimodipine (US 1%; non- 
US 20%), papaverine (US 1%; non-US 1%), verapamil (US 9%; non-US 3%) 
and other agents (US 7%; non-US 12%) including glyceryl trinitrate and 
combination pharmaceutical endovascular therapies.  
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Table 1. Respondents’ countries of practice (n) 
Australia & New 
Zealand  
(27) France       (9) Jordan         (1) South Africa  (2) 
Austria        (11) Germany    (9) Latvia           (1) Spain          (13) 
Belgium         (3) Hungary     (1) Netherlands  (5) Sweden        (5) 
Canada     (1) India           (1) Pakistan       (1) Switzerland  (9) 
Croatia          (1) Indonesia   (1) Poland         (1) Turkey          (3) 
Denmark       (4) Ireland        (1) Portugal        (6) UK              (32) 
Egypt            (1) Italy            (11) Russia          (2) USA          (177) 
Finland       (1) Japan           (1) Serbia           (3)   
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Highlights 
• 344 clinicians from 32 countries reported current practices in the 
management of cerebral vasospasm 
• Transcranial doppler was the screening method of choice to detect 
cerebral vasospasm 
• The choice of first and second-line intra-arterial agents differ 
significantly between non-US and US respondents 
• Most US and non-US clinicians reported angioplasty as the best 
treatment for cerebral vasospasm 
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Abbreviations 
AANS/CNS  American Association of Neurological Surgeons/Congress of 
Neurological Surgeons 
ANZINC  Australia and New Zealand Interventional Neuroradiology 
Collaborative 
BSNR  British Society of Neuroradiology 
CTA  Computer tomography angiography 
CTP  Computer tomography perfusion 
DCI  Delayed cerebral ischemia  
DSA   Digital subtraction angiography 
EEG  Electroencephalography 
ESNR  European Society of Neuroradiology 
MRA   Magnetic resonance angiography  
MRS  Magnetic resonance spectroscopy  
SAH  Subarachnoid hemorrhage 
TCD  Transcranial doppler 
UK   United Kingdom 
US  United States of America 
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Supplemental material 1. The 13-item questionnaire regarding the 
management of cerebral vasospasm and delayed cerebral ischemia 
1 How long have you been in practice? Please select: 
 A) <5 y B) 5-10y C) >10y 
2 What is your volume of aneurysmal subarachnoid hemorrhage? Please 
select: 
 A) <25 patients/y B) 25-50 
patients/y 
C) 50-100 
patients/y 
D) >100 
patients/y 
3  How do you/your team screen for cerebral vasospasm? Please select: 
 A) Daily 
transcranial 
Doppler 
B) Routine 
computer 
tomography 
angiography 
(between days 5-
10) 
C) Routine 
angiogram 
(between days 
5-10) 
D) Other 
Please 
specify 
4 When do you institute treatment for cerebral vasospasm? Please select: 
 A) Radiographic findings of 
vasospasm 
B) Endovascular treatment 
5  What is your initial treatment for symptomatic cerebral vasospasm? 
Please select: 
 A) Maximize NICU management B) Endovascular treatment 
6  If aggressive NICU management does not alleviate symptoms do 
you/your team use endovascular methods to treat cerebral vasospasm? 
Please select: 
 A) Yes B) No 
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Please skip remainder of 
questions 
7 What is your first-line endovascular therapy to treat cerebral vasospasm? 
Please select: 
 A)Verapamil B)Milrinone C)Nicardipin
e 
D)Papaverin
e 
E) Other 
Please 
specify 
8 How often would you estimate that you see an immediate angiographic 
change after administration of your first-line endovascular agent? Please 
select: 
 A) Never B) <30% C) 50% D) 80% E) 
Always 
9 What is your second-line endovascular intra-arterial agent? Please 
select: 
 A)Verapamil B)Milrinone C)Nicardipin
e 
D)Papaverin
e 
E) Other 
Please 
specify 
10 Do you/your team use angioplasty for cerebral vasospasm? Please 
select: 
 A) Yes B) No 
If No, skip next question 
11 Angioplasty is utilized for (select as many as apply) 
 A) Proximal Vasospasm B) Distal Vasospasm 
(A2, M2, P2 etc) 
C) Never 
12 The most effective endovascular treatment for cerebral vasospasm in my 
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practice is …  
 Enter answer here 
13 In your experience, how effective is endovascular treatment for cerebral 
vasospasm? Please select: 
 A) <10% B) <50% C) >50% D) >80% 
 
